Newly Diagnosed Multiple Myeloma Cohort

The prospective single-center study included 38 patients with symptomatic MM (16 men, 22 women) aged 35 to 84 years (median—58) newly diagnosed between 09/21/2021 and 07/21/2022. The diagnosis was established in accordance with the criteria of IMWG-2014. Plasmacytomas were detected in 66% of patients at the onset of MM (in 24 patients—bone and in 1 patient—extramedullary); in 34% of patients according to instrumental (CT/MRI) investigation plasmacytomas were not detected. Table 1 shows some clinical and laboratory parameters of patients at the onset of the disease. The majority of patients (55%) were diagnosed with stage III of the disease according to Durie–Salmon. According to the ISS classification, stages I and II were determined in an equal number of patients (29%), stage III, in 24% of patients, and in another 18% of patients, the stage was not established for technical reasons. The median hemoglobin at the onset of the disease was 105.5 g/L, and the median LDH was 162 units/L. The median share of plasma cells in the myelogram was 24%.